At Outpost, our clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).
At Outpost, we are passionate about improving the lives of patients suffering from urologic and gastrointestinal disorders. By bringing innovative medicines to market, our goal is to truly advance patient care and quality of life. Our team of scientists and functional experts have extensive experience in drug development and commercialization, deep therapeutic expertise, and a shared commitment to scientific excellence and integrity.
The company’s lead product candidate, OP-687, is being studied for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Each of these disorders impacts more than 10% of people worldwide and current therapies do not provide adequate relief for a significant proportion of patients that suffer from them. We believe that OP-687, a new class of oral therapy, holds great potential to significantly improve the lives of patients
with OAB and IBS.